What is the structural origin of Semax and how does it mechanistically differ from Selank?

Semax is a heptapeptide derived from the ACTH(4-7) fragment (Met-Glu-His-Phe) with a Pro-Gly-Pro C-terminal addition to improve metabolic stability. It does not act through the corticotropic axis but instead exerts its primary research effects through modulation of neurotrophic factor signaling and monoaminergic neurotransmission. Selank is a synthetic hexapeptide derived from tuftsin (Thr-Lys-Pro-Arg), an endogenous tetrapeptide with immunomodulatory properties, extended with a Gly-Glu-Asp sequence for stability. Selank's primary mechanism involves modulation of the GABAergic system — specifically GABA-A receptor subunit gene expression and enkephalin metabolism — producing anxiolytic effects in preclinical models without sedation or dependence-associated profiles. The two peptides target divergent neurological pathways: Semax through BDNF/NGF upregulation and dopaminergic signaling, Selank through GABAergic and serotonergic modulation. This mechanistic divergence makes them complementary research tools for studying stress-cognition interactions.

What does published evidence show about Semax and BDNF upregulation in preclinical models?

The most consistently documented molecular effect of Semax in preclinical research is upregulation of brain-derived neurotrophic factor (BDNF) in hippocampal and cortical tissue. Research in rodent models has demonstrated that Semax administration significantly increases BDNF mRNA and protein expression — with some studies documenting a tripling of hippocampal BDNF mRNA following single-administration protocols. BDNF upregulation is associated with enhanced synaptic plasticity, neuronal survival, and memory consolidation in animal models. A 2025 study (PMID 41479572) in a rodent model of Alzheimer's-like pathology demonstrated reduced amyloid burden and cognitive improvement following Semax administration, extending its potential research applications beyond acute neuroprotection to neurodegeneration models. Semax is approved for clinical use in Russia for cerebrovascular and cognitive indications, though this approval predates the evidentiary standards required by FDA or EMA regulatory frameworks.

What is the regulatory status of Semax and Selank for research in the United States?

Semax holds a Withdrawn designation under the FDA's 503A bulk drug substance program — the most restrictive status among the neuropeptides commonly studied in this context. A Withdrawn designation indicates the compound was previously removed from active consideration for the 503A Bulks List, distinguishing it from Category 2 compounds like BPC-157 and TB-500, which remain in a holding position pending re-evaluation. This status is a central issue in the July 2026 FDA PCAC meeting agenda. Selank does not currently appear on the primary PCAC agenda for July 2026. Neither compound is an FDA-approved pharmaceutical in the United States. Researchers wishing to work with these compounds should confirm current compliance requirements with legal counsel familiar with FDA compounding regulations, as the July 2026 PCAC determinations may materially affect domestic availability through compounding channels.

Semax and Selank: Neuropeptide Research from Russian Science

Semax and Selank are two synthetic neuropeptides developed at Russian research institutions that have accumulated a body of published pharmacological literature, primarily from laboratories in Moscow and St. Petersburg. Both compounds have been approved for limited medical use within Russia; this overview summarizes the published scientific research and is intended for research reference only — it does not constitute medical advice.

Semax: Structural Basis and Origins

Semax is a heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences (IMG RAS). It was designed as a synthetic analogue of the adrenocorticotropic hormone (ACTH) fragment ACTH(4-10), with the core pharmacophore sequence MEHFPG corresponding to ACTH(4-9) and a C-terminal Pro extension (designated PGP) added to confer metabolic stability.

ACTH(4-7)PGP is the common abbreviated designation in Russian literature. Unlike ACTH itself, Semax does not bind to melanocortin receptors (MC2R) involved in adrenocortical steroidogenesis, meaning it does not stimulate cortisol production — a distinction consistently noted in the Russian pharmacological literature.

The compound is registered in Russia as a nasal spray formulation for cognitive and neurological applications under the trade name Semax, with a registration that has existed since the 1990s.

See the Semax compound library entry for the molecular sequence, CAS registry number, and synthesis references.

BDNF and NGF Upregulation

The most pharmacologically significant findings in Semax research involve upregulation of neurotrophic factors, particularly brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF).

Dolotov et al. (2006, Journal of Neurochemistry) reported that intranasal Semax administration to rats produced significant elevation of BDNF mRNA and protein in the hippocampus and basal forebrain within 24 hours of administration. The effect was dose-dependent and persisted for several days after a single dose. Mechanistically, the authors proposed Semax may activate BDNF expression through melanocortin-independent pathways, potentially involving direct effects on cortical neurotrophic gene expression programs.

Inozemtseva et al. (2006, Doklady Biological Sciences) reported parallel findings for NGF upregulation in rat hippocampus, with a pattern suggesting Semax preferentially increases neurotrophin expression in limbic and cortical regions.

The significance of BDNF elevation in the context of neuroprotection, synaptic plasticity, and neurogenesis is well-established through the broader neurotrophic factor literature (Bhanu & Bhattacharya, Frontiers in Neuroscience, 2020), providing a mechanistic rationale for Semax's observed effects in stroke and cognitive research models.

Stroke Research

Semax has been most extensively studied in the context of cerebral ischemia, both in rodent models and in small human clinical trials conducted in Russia.

Gusev et al. (1997, Cerebrovascular Diseases) published an early small clinical study of Semax administered intranasally to patients with acute ischemic stroke, reporting improvements in neurological deficit scores compared to controls. The study was limited in scale (n = 60) and has not been replicated in large multicenter trials following modern stroke trial methodology.

In rodent ischemia models, Semax administration has been reported to reduce infarct volume, decrease oxidative stress markers, and attenuate neuroinflammatory gene expression (Agapova et al., Journal of Neurochemistry, 2007). These preclinical findings have formed the basis for continued interest in Semax as a potential neuroprotective tool in research settings.

Selank: Structure and Development

Selank is a synthetic hexapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, developed at the same IMG RAS as Semax. It was designed as a stable analogue of tuftsin — the endogenous tetrapeptide Thr-Lys-Pro-Arg generated by cleavage of the heavy chain of IgG — extended with the tripeptide PGP sequence for metabolic stabilization.

Tuftsin is an immunomodulatory peptide that also exhibits anxiolytic and nootropic properties in animal models, having been characterized since the 1970s (Najjar et al., Journal of Biological Chemistry, 1981). Selank was designed to capture these properties in a more stable molecular scaffold.

See the Selank compound library entry for structural comparison with tuftsin and receptor binding data.

Anxiolytic Effects and GABA System Modulation

Selank's most consistently reported pharmacological property in animal research is anxiolytic activity without the sedation, cognitive impairment, or dependence liability characteristic of benzodiazepines.

Kozlovskaya et al. (2002, Bulletin of Experimental Biology and Medicine) demonstrated anxiolytic effects of Selank in multiple rodent anxiety models including elevated plus-maze, open field, and conflict test paradigms. The compound consistently reduced anxiety-related behaviors at doses that did not impair motor coordination or produce sedation, a profile described as "anxioselective."

Regarding mechanism, Nerush et al. and colleagues at IMG RAS have proposed that Selank modulates GABAergic neurotransmission — either through indirect effects on GABA-A receptor expression or through enkephalinase inhibition that modulates endogenous opioid tone — as partial mechanisms for its anxiolytic profile. The precise receptor-level mechanism remains incompletely characterized.

Semenova et al. (2010, Bulletin of Experimental Biology and Medicine) also reported that Selank exhibits neuroprotective properties in rodent models of stress-induced memory impairment, with treated animals showing preserved memory consolidation under restraint stress conditions that produced measurable deficits in controls.

Immune Modulation Research

As a tuftsin analogue, Selank also carries a published immune biology profile. Tuftsin itself is known to stimulate phagocytosis in macrophages and neutrophils, and several Russian publications have reported that Selank exhibits immunostimulatory properties in ex vivo immune cell assays.

Uchakina et al. (2008, Russian Journal of Immunology) reported that Selank treatment in a small clinical sample of patients with anxiety disorders produced normalization of IL-6 and other cytokine profiles, framing Selank as a possible anxiolytic-immunomodulatory agent. This dual pharmacological profile aligns with the tuftsin lineage but human evidence remains preliminary.

Institute of Molecular Genetics Research Context

Both Semax and Selank research has been coordinated through the Institute of Molecular Genetics of the Russian Academy of Sciences (IBMG RAN), Moscow, which has had a longstanding neuropeptide pharmacology program spanning several decades. Key researchers in this program have included N.F. Myasoedov and his colleagues.

The institute developed a small production facility for nasal spray formulations of both compounds, which achieved Russian regulatory approval as pharmaceutical agents. This approval, however, is within Russia's regulatory system and does not constitute FDA or EMA approval; the compounds are not approved for medical use in the United States, European Union, or most other jurisdictions.

Research Limitations

The Semax and Selank literature shares characteristics with other peptide research programs emanating from former Soviet scientific institutions:

The majority of published work involves Russian-language publications or translations into indexed English journals; large-scale independent replication in Western research settings is sparse
Human clinical trial data is limited to small studies without modern randomization, blinding, and sample-size standards
Receptor identification — the specific molecular targets mediating Semax's BDNF-inducing effects and Selank's anxiolytic activity — remain incompletely defined
No Phase 2 or Phase 3 multinational clinical trials have been conducted or reported

These limitations define the current state of the evidence and should inform how researchers weight preclinical and small clinical findings.

All content on ClinicalPeptide.org summarizes peer-reviewed scientific literature for research and educational reference. No content constitutes medical advice or guidance for human use.